** German drug development company Evotec are seen up around 20% in Lang&Schwarz premarket indications after biotech company Halozyme made a 2 billion euro($2.11 billion) buyout offer to the company
** It said it intends to buy all shares of Evotec at 11 euros per share, which corresponds to a premium of 27.5% as per Thursday closing price
** On Monday Evotec rose on the news of private investment firm Triton buying over 9% stake in the company and considering a potential buyout
** The news on Halozyme might spark a takeover battle, a local trader said
** Evotec said in a statement it will analyze the expression of interest from Halozyme and decide on next steps
($1 = 0.9493 euros)
(Reporting by Isabel Demetz)
((Isabel.demetz@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.